Zambia is set to sign a five-year health financing agreement with the United States worth approximately US$3.6 billion, following negotiations that resulted in the removal of provisions requiring the sharing of individual patient data and biological specimens with the US government.
Zambian Health Minister Roma Chilengi said the agreement, scheduled for signing on Thursday, 8 October, represents a combined commitment from the two governments. According to Zambia’s Ministry of Health, the United States is expected to provide about US$1.516 billion, while Zambia will contribute approximately US$2.107 billion over the five-year period.
The agreement marks a significant adjustment from the terms that had previously stalled negotiations. Chilengi said provisions concerning individual health information had been removed and that Zambia would not be required to send biological specimens to the United States under the revised memorandum of understanding.
The negotiations reflect a wider debate across Africa over how international health partnerships should balance external financing with national control over health information, biological resources and the potential commercial value of research. Zambia’s position has been that international cooperation should strengthen its health system without creating obligations that compromise the country’s ability to determine how sensitive health resources are used.
A changing model of US health cooperation
The Zambian agreement comes as Washington reshapes its approach to health assistance in Africa under President Donald Trump’s administration. The United States has increasingly pursued country-by-country health agreements that place greater emphasis on domestic financing by African governments while reducing reliance on US assistance over time. The approach follows the dismantling of the US Agency for International Development and a broader restructuring of American foreign assistance.
For Zambia, however, the issue has not simply been the scale of American financing. The negotiations have also highlighted questions about data sovereignty, intellectual property, biological specimens and benefit-sharing.
The concerns are not unique to Zambia. The United States has concluded health agreements with a number of African countries containing provisions on health information and specimens. According to agreements published by the US State Department and reviewed by the Associated Press, some arrangements require participating countries to provide information and specimens following a US request. The provisions are intended to support surveillance and research into infectious diseases with epidemic or pandemic potential, while allowing research material to be made available to US non-government entities.
The debate has centred partly on whether African countries supplying data or biological material would receive meaningful and timely access to medicines, diagnostics or other products developed from those resources. Existing agreements have included language making access to resulting products dependent on funding availability and US domestic priorities.
For African governments, the question therefore extends beyond privacy. It concerns who controls valuable health information and biological resources, who participates in scientific development, and how the economic and medical benefits of research are distributed.
Zambia takes a different route
Zambia’s decision to renegotiate rather than abandon the partnership illustrates a more differentiated approach to international health financing. Lusaka has maintained that the United States remains an important health partner while seeking changes to provisions it considered unsuitable.
Chilengi has said the final agreement addresses Zambia’s concerns around specimen sharing and individual patient information. The government has also indicated that the agreement was reviewed through its domestic governmental processes before approval.
Importantly, the full memorandum has not been publicly released ahead of the signing. This means that the precise wording and implementation mechanisms cannot yet be independently assessed in their entirety. The government’s assurances concerning data and specimen provisions therefore remain based primarily on statements from the Zambian authorities until the agreement itself becomes available.
The distinction is significant. The removal of explicit specimen-sharing and individual patient-data provisions would represent a substantive change, but the wider operation of the agreement, including monitoring, financing schedules, intellectual-property arrangements and implementation responsibilities, will ultimately determine its practical implications.
A regional debate over health sovereignty
Zambia’s negotiations have unfolded alongside disagreements elsewhere on the continent. Zimbabwe rejected a proposed US health agreement earlier this year, with government officials raising concerns about health data and specimen-sharing requirements. The United States subsequently ended its health assistance to Zimbabwe at the end of September.
Namibia and Ghana have similarly raised objections to elements of proposed US health arrangements. In Ghana’s case, President John Dramani Mahama said the government rejected terms it considered unacceptable, including concerns over access to information and medical products.
These developments suggest that African governments are increasingly seeking to define the terms under which external health assistance operates rather than treating donor financing as separate from questions of sovereignty and national development.
For Zambia, the forthcoming agreement offers both an immediate financial opportunity and a test of that negotiating position. The combined US$3.6 billion commitment could provide substantial support for health services, while the greater financial contribution expected from the Zambian government is intended to reinforce domestic responsibility for sustaining programmes beyond the life of US assistance.
The agreement consequently represents more than a bilateral funding arrangement. It is also part of a broader shift in African health diplomacy, in which governments are seeking international partnerships while placing greater emphasis on control over national health systems, data and biological resources.
The outcome of Zambia’s negotiations may therefore be watched beyond Lusaka, particularly by governments considering how to secure external health financing without relinquishing authority over resources that are increasingly important to public health, scientific research and economic value.
